share_log

石藥集團:自願公告 - 高選擇性MAT2A抑制劑(SYH2039)獲臨床試驗批准

CSPC PHARMA: VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE MAT2A INHIBITOR (SYH2039)OBTAINS CLINICAL TRIAL APPROVAL

香港交易所 ·  Mar 18 06:08
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more